Vertex Pharmaceuticals Aktie 983327 / US92532F1003
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
|
18.09.2025 19:26:15
|
Vertex Pharmaceuticals Secures Italian Reimbursement Agreement For Gene-Edited Therapy CASGEVY
(RTTNews) - Vertex Pharmaceuticals (VRTX), Thursday announced a reimbursement agreement with the Italian Medicines Agency that allows eligible transfusion-dependent beta thalassemia and severe sickle cell disease patients to access the CRISPR/Cas9 gene-edited therapy CASGEVY.
CASGEVY, a non-viral ex vivo CRISPR/Cas9 gene-edited cell therapy, is designed to produce high levels of fetal hemoglobin in red blood cells, reducing or eliminating vaso-occlusive crises for SCD patients and transfusion needs for TDT patients.
VRTX is currently trading at $387.05, down $0.10 or 0.03 percent on the Nasdaq.